Brian Best
Vorstandsvorsitzender bei Ariste Medical, Inc.
Profil
Brian Best is the founder of Predigen, Inc. He is currently the Chief Executive Officer of Ariste Medical, Inc. and the Director of Biomeme, Inc. He was previously the Senior Director-Clinical Affairs at ArgiNOx Pharmaceuticals, Inc., a Principal at Abbott Laboratories, COR Therapeutics, Inc., and Millennium Pharmaceuticals, Inc., the Vice President-Marketing at Medicure, Inc., and the Vice President-Commercial Operations at Tethys Bioscience, Inc. He also held a position as Principal at PDL BioPharma, Inc. Mr. Best received his undergraduate degree from Wake Forest University.
Aktive Positionen von Brian Best
Unternehmen | Position | Beginn |
---|---|---|
Ariste Medical, Inc.
Ariste Medical, Inc. Medical SpecialtiesHealth Technology Ariste Medical, Inc. develops drug eluting surgical implants to prevent common causes of device failure. It enables the application and elution of drugs from devices made from PTFE, slippery surface known to man, as well as other materials, including polypropylene and polyurethane. The company was founded by Lisa H. Jennings in 2007 and is headquartered in Memphis, TN. | Vorstandsvorsitzender | - |
Predigen, Inc.
Predigen, Inc. BiotechnologyHealth Technology Predigen, Inc. operates as a molecular diagnostics company creating a new generation of tests for infectious and inflammatory diseases. The company was founded by Geoffrey Ginsburg, Christopher Woods, Ephraim Tsalik, Geoffrey Ling, Donna Crenshaw and Brian Best in 2016 and is headquartered in Gig Harbor, WA. | Gründer | - |
Biomeme, Inc.
Biomeme, Inc. Miscellaneous Commercial ServicesCommercial Services Biomeme, Inc. designs advanced mobile Apps for iphone. The company was founded by Marc DeJohn, Max Perelman and Jesse vanWestrienen in 2012 and is headquartered in Philadelphia, PA. | Direktor/Vorstandsmitglied | 09.09.2021 |
Ehemalige bekannte Positionen von Brian Best
Unternehmen | Position | Ende |
---|---|---|
MEDICURE INC. | Vertrieb & Marketing | - |
ABBOTT LABORATORIES | Corporate Officer/Principal | - |
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Corporate Officer/Principal | - |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
PDL BIOPHARMA, INC. | Corporate Officer/Principal | - |
Ausbildung von Brian Best
Wake Forest University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ABBOTT LABORATORIES | Health Technology |
MEDICURE INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
COR Therapeutics, Inc.
COR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology COR Therapeutics, Inc.. The principal activities of the Company are the discovery, development and commercialization of novel pharmaceutical products to establish new standards of care for the treatment and prevention of severe cardiovascular diseases. Integrilin was the Company's first product taken from discovery to commercialization. A drug was approved to treat patients who undergo a procedure known as angioplasty to open blood vessels. This drug has also been approved to treat patients with intermittent chest pains known as unstable angina and patients suffering from a kind of Heart attack known as non-Q-wave myocardial infraction | Health Technology |
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
ArgiNOx Pharmaceuticals, Inc.
ArgiNOx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ArgiNOx Pharmaceuticals, Inc. focused on the discovery and development of medicines to treat hospitalized patients. The company's initial area of research and development is directed at nitric oxide-mediated pathways. Arginox's lead compound, Tilarginine Acetate Injection, is in late-stage clinical evaluation for the treatment of cardiogenic shock. The company was incorporated on March 24, 2004 and was headquartered in Redwood City, CA. | Health Technology |
Tethys Bioscience, Inc.
Tethys Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Tethys Bioscience was dedicated to the discovery, development and commercialization of novel biological markers biomarkers that provided a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes. By developing new tests that used protein and other blood borne biomarkers to identify people at high risk for devastating and preventable diseases, they can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers gave a snapshot of an individual's current risk, which may be modifiable. Their goal was to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Their research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk. The company had become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: The company had built expertise, created significant intellectual property, and was executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. It was focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients. | Health Technology |
Ariste Medical, Inc.
Ariste Medical, Inc. Medical SpecialtiesHealth Technology Ariste Medical, Inc. develops drug eluting surgical implants to prevent common causes of device failure. It enables the application and elution of drugs from devices made from PTFE, slippery surface known to man, as well as other materials, including polypropylene and polyurethane. The company was founded by Lisa H. Jennings in 2007 and is headquartered in Memphis, TN. | Health Technology |
Biomeme, Inc.
Biomeme, Inc. Miscellaneous Commercial ServicesCommercial Services Biomeme, Inc. designs advanced mobile Apps for iphone. The company was founded by Marc DeJohn, Max Perelman and Jesse vanWestrienen in 2012 and is headquartered in Philadelphia, PA. | Commercial Services |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Predigen, Inc.
Predigen, Inc. BiotechnologyHealth Technology Predigen, Inc. operates as a molecular diagnostics company creating a new generation of tests for infectious and inflammatory diseases. The company was founded by Geoffrey Ginsburg, Christopher Woods, Ephraim Tsalik, Geoffrey Ling, Donna Crenshaw and Brian Best in 2016 and is headquartered in Gig Harbor, WA. | Health Technology |